Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron’s antibody cocktail seems to reduce levels ... It will be used to identify patients most likely to benefit from the treatment and the next cohort could be used to confirm the results.

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Regeneron Pharmaceuticals today announced financial results for the fourth quarter and full year 2024 and provided a business ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

Treatment discontinuations due to adverse reactions occurred ... endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-founder, president ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

US FDA revokes authorization for four COVID antibody drugs Healthcare & Pharmaceuticalscategory ... protein while testing a COVID-19 treatment. Regeneron loses key defense in COVID-19 treatment ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...